Tagged with GE

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has with France, general manager Jerome Bouyer offers an optimistic view of how the French healthcare sector can best be structured…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Pharmaceuticals Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened: you were made European CEO in 2015 for having steered Dompé through considerable renewal and restructuring, the company also embarked…

Pharma Pharmaceuticals Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device and pharmaceutical companies is crucial. What role can BD, as one of the world’s leading companies specializing in medical devices,…

Pharma “My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges and set the economy on a stronger growth trajectory,” says October Pharma CEO Ahmed Zaghloul You were last interviewed by…

Pharma The founder of the Middle East’s largest pharmaceutical company, EIPICO, discusses the evolution of the Egyptian pharmaceutical industry over the last 50 years, and his hopes for the industry over the coming decades. Dr. Borhan, you became Chairman of El Kahira Pharmaceuticals in 1962, and established EIPICO in 1980. In…

Pharma Eva Pharma is one of the fastest growing pharmaceutical companies in the MENA region, and CEO Riad Armanious is aiming to take the company from the 21st ranked generic company at the regional level to third over the next five years, while building business and operations on the ground in…

Pharma The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition and build…

Pharma While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research. Clinical Trial Manager, Patrick Winkler, and Senior Business Development Executive, Geoffrey Bilon, share the service offerings of Medpace, as well…

Pharma Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how already forty-five percent of their business is done overseas; and how on current projections, excluding external growth, they anticipate to…